{
  "actions": [
    {
      "acted_at": "2015-02-25", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2015-02-27", 
      "in_committee": null, 
      "references": [], 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr1066-114", 
  "bill_type": "hr", 
  "by_request": false, 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }
  ], 
  "congress": "114", 
  "cosponsors": [
    {
      "district": "8", 
      "name": "Bucshon, Larry", 
      "sponsored_at": "2015-03-04", 
      "state": "IN", 
      "thomas_id": "02018", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "4", 
      "name": "Pompeo, Mike", 
      "sponsored_at": "2015-02-25", 
      "state": "KS", 
      "thomas_id": "02022", 
      "title": "Rep", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2015-02-25", 
  "number": "1066", 
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to promote the use of adaptive trial designs, Bayesian methods, and other innovative statistical methods in clinical protocols for drugs, biological products, and devices, and with respect to the requirement to conduct postapproval studies and clinical trials, and for other purposes.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Clinical Trials Modernization Act of 2015", 
  "sponsor": {
    "district": "27", 
    "name": "Collins, Chris", 
    "state": "NY", 
    "thomas_id": "02151", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2015-02-25", 
  "subjects": [
    "Administrative law and regulatory procedures", 
    "Administrative remedies", 
    "Department of Health and Human Services", 
    "Drug safety, medical device, and laboratory regulation", 
    "Food and Drug Administration (FDA)", 
    "Health", 
    "Health technology, devices, supplies", 
    "Medical research"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2015-02-25", 
    "text": "Clinical Trials Modernization Act of 2015\n\nThis bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to allow sponsors of applications for new drugs, biological products, and medical devices to propose incorporation of alternative statistical methods, including adaptive trial design and Bayesian methods, into clinical trial protocols and marketing applications.\n\nThe FDA is required to issue guidance that establishes or clarifies standards for using alternative statistical methods in clinical trials.\n\nThe FDA must establish a process under which a post-approval study or clinical trial required by the FDA is periodically evaluated to determine whether the trial or study is no longer scientifically warranted or whether the design should be renegotiated because of changes in medical practice or the standard of care."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Clinical Trials Modernization Act of 2015", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to promote the use of adaptive trial designs, Bayesian methods, and other innovative statistical methods in clinical protocols for drugs, biological products, and devices, and with respect to the requirement to conduct postapproval studies and clinical trials, and for other purposes.", 
      "type": "official"
    }
  ], 
  "updated_at": "2016-06-25T06:32:10-04:00", 
  "url": "http://thomas.loc.gov/cgi-bin/bdquery/z?d114:HR1066:@@@L&summ2=m&"
}